Trelstar

Advanced Prostate Cancer

Trelstar is indicated for the palliative treatment of advanced prostate cancer. It is used to help manage symptoms in patients whose cancer has progressed or spread beyond the prostate gland.

This medication is primarily used to:

• Relieve symptoms caused by advanced prostate tumors.
• Slow the growth of cancer cells by reducing the body's production of certain hormones.
• Provide a treatment option when the cancer is no longer localized to the prostate.

Trelstar is intended to help control the disease and its symptoms, but it is not a cure for prostate cancer.

Mechanism of Action

Trelstar belongs to a class of medications known as gonadotropin-releasing hormone (GnRH) agonists. It works by affecting the signals the brain sends to the testicles to produce testosterone.

The process typically occurs in the following stages:

• Initial Flare: When treatment first begins, there is a temporary increase in the amount of testosterone the body produces. This is sometimes called a testosterone flare.
• Pituitary Suppression: With continued use, Trelstar causes the pituitary gland to stop responding to the signals that trigger hormone production.
• Hormone Reduction: As a result, the testicles stop producing testosterone. Within a few weeks of starting treatment, testosterone levels usually drop to very low levels, similar to the levels seen after surgical removal of the testicles.

Because many types of prostate cancer cells require testosterone to grow and spread, reducing the amount of this hormone in the body can help manage the disease and slow the progression of the cancer.

Common Side Effects

• Hot flashes
• Pain, swelling, or redness at the injection site
• Bone, joint, or muscle pain
• Headache or dizziness
• Nausea, vomiting, diarrhea, or constipation
• Decreased sexual desire or impotence
• Breast enlargement or tenderness
• Leg or back pain
• Feeling tired or weak

Serious Side Effects

Contact a healthcare provider immediately if you experience any of the following:

• Difficulty urinating, painful urination, or blood in the urine
• Severe back pain or numbness and weakness in the legs
• Loss of bladder or bowel control
• Chest pain, shortness of breath, or irregular heartbeat
• Sudden numbness or weakness, especially on one side of the body
• Vision changes or sudden, severe headache
• Signs of high blood sugar, such as increased thirst, frequent urination, or fruity breath odor
• New or worsening depression or mood changes
• Signs of a severe allergic reaction, including rash, hives, or swelling of the face, lips, or throat

During the first few weeks of treatment, testosterone levels may briefly increase before they drop. This can cause a temporary worsening of prostate cancer symptoms, such as increased bone pain or urinary problems. This is often referred to as a tumor flare.

Initial Symptom Worsening

During the first few weeks of treatment, Trelstar causes a temporary increase in testosterone levels. This may lead to a tumor flare, where prostate cancer symptoms briefly worsen. In some cases, this can cause serious complications such as spinal cord compression or urinary tract blockage. Monitoring is typically closer during the first month of therapy.

Heart Disease and Diabetes

There is an increased risk of developing diabetes or experiencing serious cardiovascular events, including heart attack, stroke, or sudden cardiac death, while using this class of medication. Healthcare providers may monitor blood glucose levels and heart health periodically during treatment.

Bone Health

Long-term use of Trelstar may lead to a decrease in bone mineral density. This can increase the risk of developing osteoporosis or bone fractures.

Allergic Reactions

Serious allergic reactions, including anaphylaxis, have been reported. Signs of a reaction may include hives, difficulty breathing, or swelling of the face and throat.

Other Precautions

• Pituitary Apoplexy: Rare cases of pituitary gland issues have occurred, often within the first two weeks of treatment. Symptoms include sudden headache, vomiting, and vision changes.
• Heart Rhythm: This medication may affect the electrical activity of the heart (QT prolongation), especially if used with other drugs that have similar effects.
• Pregnancy: Trelstar can cause fetal harm and is not intended for use in women who are or may become pregnant.

Pregnancy Considerations

Trelstar is not intended for use in women who are pregnant or may become pregnant. Clinical data suggests that the medication can cause fetal harm, including birth defects or miscarriage, if administered during pregnancy. If a patient becomes pregnant while receiving this medication, they should notify their healthcare provider immediately.

Contraception

Individuals of childbearing potential should use effective, non-hormonal contraception during treatment. Because Trelstar alters hormone levels, hormonal birth control methods may not be reliable. It is typically recommended to continue using barrier methods, such as condoms or a diaphragm, for the duration of treatment and for a specific period after the final injection.

Breastfeeding

It is currently unknown if triptorelin, the active ingredient in Trelstar, passes into human breast milk. Because of the potential for serious adverse reactions in a nursing infant, healthcare providers generally advise against breastfeeding while using this medication. A decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the treatment to the patient.

Fertility

Treatment with Trelstar suppresses the production of reproductive hormones. This may lead to a reduction in fertility in both men and women. While hormone levels often return to normal after the medication is discontinued, the long-term effects on the ability to conceive are not fully established.

Trelstar is supplied as a lyophilized powder in vials. Before administration, the powder is mixed with a diluent to form a suspension.

Administration Method

• The medication is administered as an intramuscular injection.
• It is typically injected into the muscle of the buttock.
• The injection is performed by a healthcare professional in a clinical setting.

Different formulations of the powder are available to provide medication over various time intervals.

FDA Approval and Indications

Trelstar (triptorelin pamoate) is FDA-approved for the palliative treatment of advanced prostate cancer. It functions as a gonadotropin-releasing hormone (GnRH) agonist, which works by reducing the amount of testosterone the body produces. This reduction helps slow or stop the growth of cancer cells that depend on testosterone.

Safety Communications

The FDA has issued safety communications regarding the class of drugs that includes Trelstar. Based on an ongoing safety review, the FDA notified healthcare professionals about a potential small increased risk of certain conditions in men receiving GnRH agonists for prostate cancer, including:

• Diabetes
• Heart attack
• Stroke
• Sudden cardiac death

The FDA requires manufacturers of these drugs to include information about these potential risks in the product labeling. Healthcare providers are advised to monitor patients for the development of cardiovascular disease and diabetes while they are receiving treatment.

Regulatory Status and Administration

Trelstar is a prescription-only medication. It is administered as an intramuscular injection by a healthcare professional. There are currently no Risk Evaluation and Mitigation Strategy (REMS) programs or active recalls associated with Trelstar according to available regulatory records.

Cost Factors

The cost of Trelstar is influenced by the specific formulation prescribed by your doctor. It is available in three strengths that are administered at different intervals: monthly, every three months, or every six months. The price may vary depending on which schedule is used.

Because Trelstar is an intramuscular injection that must be given by a healthcare professional, the total cost often includes both the medication itself and the professional fees for the injection procedure.

Insurance and Assistance

Insurance coverage for Trelstar varies by plan. Since it is administered in a clinical setting, it is often covered under medical benefits rather than pharmacy benefits. For example, Medicare Part B frequently covers provider-administered injections for prostate cancer.

Financial assistance may be available for those who qualify. This can include:

• Co-pay assistance programs for patients with private or commercial insurance.
• Patient assistance programs for individuals without insurance or those who are underinsured.

Patients should speak with their healthcare provider or insurance company to determine their specific out-of-pocket costs and to inquire about available support programs.